# Title

 Food and Drugs. PART 610—GENERAL BIOLOGICAL PRODUCTS STANDARDS


# ID

 CFR-2018-title21-vol7.Pt. 610


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                 |
|:------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'equal to', 'within', 'more than', 'greater than', 'maximum', 'lesser', 'after', 'minimum', 'exceed', 'at least', 'prior to']                                                                                                                                                                                                                                                               |
| Duration    | ['30.0 day', '12 month', '45.0 day', '3.0 day', '12.0 week']                                                                                                                                                                                                                                                                                                                                           |
| Condition   | ['until', 'unless', 'not subject to', 'as soon as', 'where', 'if not', 'subject to', 'provided that', 'when', 'if']                                                                                                                                                                                                                                                                                    |
| Entities    | ['United States Pharmacopeia XX', 'Extraneous', 'Purity', 'Biological', 'Total', 'Streptokinase', 'West Nile', 'Package', 'Test', 'Potency', 'Donor', 'Explain', 'Cryoprecipitate', 'Identity', 'Prepare', 'Legible', 'Typography', 'Plasma', 'Labels', 'Food', 'Human', 'Normal Horse Serum', 'Retest', 'Mycoplasma', 'Name', 'Proper', 'Cell', 'Research', 'U.S', 'Appropriate', 'Sterility', 'Bar'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                    |
|:--------------|:---------------------------------------------------------------------------------------------------------------------------|
| prior to      | Tests  prior to  release required for each lot.                                                                            |
| prior to      | licensed product shall be released by the manufacturer prior to the completion of tests for conformity with standards      |
| after         | applicable test shall be made on each lot after completion of all processes of manufacture which may                       |
| equal to      | purity, potency, and effectiveness of the biological product equal to or greater than the assurances provided by the       |
| greater than  | effectiveness of the biological product equal to or greater than the assurances provided by the method or process          |
| minimum       | procedures for sterility testing that describe, at a minimum , the following: (1) The sterility test method                |
| within        | (2) For non-culture-based test methods,  within the test itself, appropriate controls must be used                         |
| exceed        | for residual moisture and shall meet and not exceed established limits as specified by an approved method                  |
| at least      | The test dose for each rabbit shall be  at least 3 milliliters per kilogram of body weight of                              |
| at least      | The test dose for each rabbit shall be  at least 3 milliliters per kilogram of body weight of                              |
| maximum       | proportionately, on a body weight basis, to the maximum single human dose recommended, but need not exceed                 |
| exceed        | maximum single human dose recommended, but need not exceed 10 milliliters per kilogram of body weight of                   |
| at least      | The test dose for each rabbit shall be  at least 3 milliliters per kilogram of body weight of                              |
| at least      | The test dose for each rabbit shall be  at least 3 milliliters per kilogram of body weight of                              |
| maximum       | proportionately, on a body weight basis, to the maximum single human dose recommended, but need not exceed                 |
| more than     | the requirements for absence of pyrogens if not more than three of the eight rabbits show individual rises                 |
| maximum       | and if the sum of the eight individual maximum  temperature rises does not exceed 3.7 &#176;C.                             |
| exceed        | the eight individual maximum temperature rises does not exceed  3.7 &#176;C.                                               |
| after         | of each lot shall be tested for identity after  all labeling operations shall have been completed.                         |
| minimum       | product to result in a decrease below the minimum acceptable potency within the dating period when stored                  |
| within        | in a decrease below the minimum acceptable potency within the dating period when stored at the recommended                 |
| exceed        | calculated concentration in the final medium shall not exceed  1:1,000,000.                                                |
| minimum       | A  minimum concentration of antibiotics, other than penicillin, may be                                                     |
| more than     | regulation, no liquid serum or antitoxin shall contain more than  20 percent total solids.                                 |
| prior to      | for Except as provided otherwise in this subchapter, prior to clarification or filtration in the case of live              |
| prior to      | for Except as provided otherwise in this subchapter, prior to clarification or filtration in the case of live              |
| minimum       | allogeneic transfusion, you must assure that, at a minimum , the first donation in each 30-day period                      |
| minimum       | must further test under this section, at a minimum , the first reactive donation in each 30                                |
| prior to      | (g) Release or shipment  prior to  testing.                                                                                |
| prior to      | of this section may be released or shipped prior to completion of testing in the following circumstances provided          |
| after         | to relevant transfusion-transmitted infections as soon as possible after release or shipment, and that you provide the     |
| more than     | anti-HBc or anti-HTLV, types I and II, on more than  one occasion;                                                         |
| within        | blood components previously donated by such a donor. within                                                                |
| after         | the following actions: (1) Within 3 calendar days after a donor tests reactive for evidence of human                       |
| before        | blood components collected: (i) Twelve months and less before the donor's most recent nonreactive screening tests, or      |
| before        | blood components collected: (i) Twelve months and less before the donor's most recent nonreactive screening tests, or      |
| lesser        | and nonreactive antibody screening test, whichever is the lesser period, you must: (A) Quarantine all previously collected |
| within        | (IDE), is exempted for such use by FDA, within 45 calendar days after the donor tests reactive                             |
| after         | such use by FDA, within 45 calendar days after the donor tests reactive for evidence of HIV                                |
| within        | must make reasonable attempts to perform the notification within 12 weeks after receiving the results of further           |
| after         | attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence           |
| after         | attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence           |
| within        | blood components previously donated by such a donor. within                                                                |
| after         | the following actions: (1) Within 3 calendar days after a donor tests reactive for evidence of hepatitis                   |
| before        | blood components collected: (i) Twelve months and less before the donor's most recent nonreactive screening tests, or      |
| before        | blood components collected: (i) Twelve months and less before the donor's most recent nonreactive screening tests, or      |
| lesser        | and nonreactive antibody screening test, whichever is the lesser period, you must: (A) Quarantine all previously collected |
| within        | (IDE), is exempted for such use by FDA, within 45 calendar days after the donor tests reactive                             |
| after         | such use by FDA, within 45 calendar days after the donor tests reactive for evidence of HCV                                |
| within        | must make reasonable attempts to perform the notification within 12 weeks after receiving the results of further           |
| after         | attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence           |
| after         | attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence           |
| exceed        | column B, storage of a product must not exceed the dating period specified in column C, unless                             |
| minimum       | partial label, the container shall show as a minimum the name (expressed either as the proper or                           |
| more than     | &#8220;no preservative&#8221;; (f) The number of containers, if more than  one;                                            |
| minimum       | (s) The statement: &#8220;&#8201;&#8216;Rx only&#8217;&#8201;&#8221; for prescription biologicals. minimum                 |
| at least      | and typeface of the proper name shall be at least as prominent as the point size and typeface                              |
| at least      | the proper name and the background shall be at least as great as the color value between the                               |
| minimum       | exported provided that in all such cases the minimum  label requirements prescribed in &#167;&#8201;610.60 are observed.   |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 30.0 day   | (i) You must test donations of human blood and blood components from a donor whose donations are dedicated to and used solely by a single identified recipient under paragraphs (a), (b), and (e) of this section; except that, if the donor makes multiple donations for a single identified recipient, you may perform such testing only on the first donation in each 30-day period.                                                                                              |
| 30.0 day   | (3) If you ship autologous donations to another establishment that does not allow autologous donations to be used for allogeneic transfusion, you must assure that, at a minimum, the first donation in each 30-day period is tested under this section.                                                                                                                                                                                                                             |
| 30.0 day   | Except:                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (1) For autologous donations:                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) You must further test under this section, at a minimum, the first reactive donation in each 30 calendar day period; or                                                                                                                                                                                                                                                                                                                                             |
|            |               (ii) If you have a record for that donor of a positive result on further testing performed under this section, you do not have to further test an autologous donation.                                                                                                                                                                                                                                                                                                 |
| 3.0 day    | (a) If you are an establishment that collects Whole Blood or blood components, including Source Plasma and Source Leukocytes, you must establish, maintain, and follow an appropriate system for the following actions:                                                                                                                                                                                                                                                              |
|            |               (1) Within 3 calendar days after a donor tests reactive for evidence of human immunodeficiency virus (HIV) infection when tested under &#167;&#8201;610.40(a) and (b) or when you are made aware of other reliable test results or information indicating evidence of HIV infection, you must review all records required under &#167;&#8201;606.160(d) of this chapter, to identify blood and blood components previously donated by such a donor.                    |
| 12 month   | For those identified blood and blood components collected:                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Twelve months and less before the donor's most recent nonreactive screening tests, or                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Twelve months and less before the donor's reactive direct viral detection test, e.g., nucleic acid test or HIV p24 antigen test, and nonreactive antibody screening test, whichever is the lesser period, you must:                                                                                                                                                                                                                                               |
|            |               (A) Quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures; and                                                                                   |
|            |               (B) Notify consignees to quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures;                                                                  |
|            |               (2) You must perform further testing for HIV as required under &#167;&#8201;610.40(e) of this chapter on the reactive donation.                                                                                                                                                                                                                                                                                                                                        |
| 12 month   | For those identified blood and blood components collected:                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Twelve months and less before the donor's most recent nonreactive screening tests, or                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Twelve months and less before the donor's reactive direct viral detection test, e.g., nucleic acid test or HIV p24 antigen test, and nonreactive antibody screening test, whichever is the lesser period, you must:                                                                                                                                                                                                                                               |
|            |               (A) Quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures; and                                                                                   |
|            |               (B) Notify consignees to quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures;                                                                  |
|            |               (2) You must perform further testing for HIV as required under &#167;&#8201;610.40(e) of this chapter on the reactive donation.                                                                                                                                                                                                                                                                                                                                        |
| 45.0 day   | (3) You must notify consignees of the results of further testing for HIV, or the results of the reactive screening test if further testing under paragraph (a)(2) of this section is not available, or if under an investigational new drug application (IND) or investigational device exemption (IDE), is exempted for such use by FDA, within 45 calendar days after the donor tests reactive for evidence of HIV infection under &#167;&#8201;610.40(a) and (b) of this chapter. |
| 12.0 week  | You must make reasonable attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence of HIV infection from the collecting establishment, or after receiving the donor's reactive screening test result for HIV if further testing is not available, or if under an IND or IDE is exempted for such use by FDA.                                                                                                                  |
| 3.0 day    | (a) If you are an establishment that collects Whole Blood or blood components, including Source Plasma and Source Leukocytes, you must establish, maintain, and follow an appropriate system for the following actions:                                                                                                                                                                                                                                                              |
|            |               (1) Within 3 calendar days after a donor tests reactive for evidence of hepatitis C virus (HCV) infection when tested under &#167;&#8201;610.40(a) and (b) of this chapter or when you are made aware of other reliable test results or information indicating evidence of HCV infection, you must review all records required under &#167;&#8201;606.160(d) of this chapter, to identify blood and blood components previously donated by such a donor.               |
| 12 month   | For those identified blood and blood components collected:                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Twelve months and less before the donor's most recent nonreactive screening tests, or                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Twelve months and less before the donor's reactive direct viral detection test, e.g., nucleic acid test and nonreactive antibody screening test, whichever is the lesser period, you must:                                                                                                                                                                                                                                                                        |
|            |               (A) Quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures; and                                                                                   |
|            |               (B) Notify consignees to quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures;                                                                  |
|            |               (2) You must perform further testing for HCV as required under &#167;&#8201;610.40(e) on the reactive donation.                                                                                                                                                                                                                                                                                                                                                        |
| 12 month   | For those identified blood and blood components collected:                                                                                                                                                                                                                                                                                                                                                                                                                           |
|            |               (i) Twelve months and less before the donor's most recent nonreactive screening tests, or                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (ii) Twelve months and less before the donor's reactive direct viral detection test, e.g., nucleic acid test and nonreactive antibody screening test, whichever is the lesser period, you must:                                                                                                                                                                                                                                                                        |
|            |               (A) Quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures; and                                                                                   |
|            |               (B) Notify consignees to quarantine all previously collected in-date blood and blood components identified under paragraph (a)(1) of this section if intended for use in another person or for further manufacture into injectable products, except pooled blood components intended solely for further manufacturing into products that are manufactured using validated viral clearance procedures;                                                                  |
|            |               (2) You must perform further testing for HCV as required under &#167;&#8201;610.40(e) on the reactive donation.                                                                                                                                                                                                                                                                                                                                                        |
| 45.0 day   | (3) You must notify consignees of the results of further testing for HCV, or the results of the reactive screening test if further testing is not available, or if under an investigational new drug application (IND) or investigational device exemption (IDE), is exempted for such use by FDA, within 45 calendar days after the donor tests reactive for evidence of HCV infection under &#167;&#8201;610.40(a) and (b).                                                        |
| 12.0 week  | You must make reasonable attempts to perform the notification within 12 weeks after receiving the results of further testing for evidence of HCV infection from the collecting establishment, or after receiving the donor's reactive screening test result for HCV if further testing is not available, or if under an IND or IDE, is exempted for such use by FDA.                                                                                                                 |


## Condition

| Condition      | Context                                                                                                                                                 |
|:---------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------|
| when           | except that a test result may be disregarded when it is established that the test is invalid                                                            |
| until          | shall not distribute a lot of a product until the lot is released by the Director, Center                                                               |
| when           | and Research, shall not issue such notification except when deemed necessary for the safety, purity, or potency                                         |
| until          | not distribute a lot of a biological product until the lot is released by the Director, Center                                                          |
| when           | and Research shall not issue such notification except when deemed necessary for the safety, purity, or potency                                          |
| if             | a minimum: (A) Composition of the culture media; if                                                                                                     |
| if             | acceptance criteria; and (C) Controls used to ver if y the method's ability to detect the presence                                                      |
| if             | quantity or concentration of inhibitors, neutralizers, and preservatives, if present, in the tested material; (5) For a                                 |
| if             | faulty materials used in conducting the sterility testing. if                                                                                           |
| unless         | does not comply with the sterility test requirements unless a thorough investigation by the quality control unit                                        |
| if             | a sterility test may be repeated one time. if                                                                                                           |
| if             | the manufacturing process from which it was obtained. if                                                                                                |
| if             | required to comply with the sterility test requirements if the Director of the Center for Biologics Evaluation                                          |
| when           | the Director, Center for Drug Evaluation and Research, when deemed not necessary for the continued safety, purity,                                      |
| if not         | lot meets the requirements for absence of pyrogens if not more than three of the eight rabbits show                                                     |
| if             | lot meets the requirements for absence of pyrogens if not more than three of the eight rabbits                                                          |
| when           | the minimum acceptable potency within the dating period when  stored at the recommended temperature.                                                    |
| when           | for use with the jet injector; dried vaccines when the accompanying diluent contains a preservative; or to                                              |
| unless         | adjuvant shall not be introduced into a product unless there is satisfactory evidence that it does not                                                  |
| if             | biological product shall not exceed: (1) 0.85 milligrams if  determined by assay;                                                                       |
|                |               (2) 1.14 milligrams                                                                                                                       |
| if             | biological product shall not exceed: (1) 0.85 milligrams if  determined by assay;                                                                       |
|                |               (2) 1.14 milligrams                                                                                                                       |
| provided that  | added; or (3) 1.25 milligrams determined by assay provided that data demonstrating that the amount of aluminum used                                     |
| not subject to | a very limited number of population doublings are not subject to  the provisions of this paragraph (c).                                                 |
| if             | been found acceptable for this purpose by FDA. if                                                                                                       |
| if             | procedures found acceptable for this purpose by FDA. if                                                                                                 |
| when           | (i) You must test for evidence of infection when the following conditions are met: (A) A test(s)                                                        |
| unless         | You must perform this testing on each donation, unless one of the following exceptions applies: (A) Testing                                             |
| when           | or blood component, or other information related to when and how a donation is at risk of                                                               |
| if             | to and used solely by a single ident if ied recipient under paragraphs (a), (b), and (e)                                                                |
| unless         | transfusion-transmitted infections listed in &#167;&#8201;630.3(h)(iv) of this chapter unless  the final device contains viable leukocytes.             |
| if             | samples of blood, blood components, plasma, or sera if used or distributed for clinical laboratory testing or                                           |
| if             | all autologous donations are tested under this section. if                                                                                              |
| if             | to that establishment are tested under this section. if                                                                                                 |
| if             | each 30-day period is tested under this section. if                                                                                                     |
| when           | using a licensed, approved, or cleared supplemental test, when  available.                                                                              |
| if             | not have to further test an autologous donation. if                                                                                                     |
| provided that  | to completion of testing in the following circumstances provided that you label the blood or blood components under                                     |
| as soon as     | evidence of infection due to relevant transfusion-transmitted infections as soon as possible after release or shipment, and that you                    |
| unless         | are collected from a donor deferred under &#167;&#8201;610.41(a) unless you meet the following conditions: (A) Except for                               |
| if             | for evidence of infection due to the ident if ied relevant transfusion-transmitted infection(s); (D) If the blood                                       |
| if             | samples of blood, blood components, plasma, or sera if used or distributed for clinical laboratory testing or                                           |
| when           | (v) Anti-HBc reactive donations, otherwise nonreactive  when tested as required under this section, may be                                              |
| if             | as required under paragraph (a) of this section if , the donation is further tested by an                                                               |
| if             | required under &#167;&#8201;640.65(a)(2)(ii) and (b)(1)(i) of this chapter, if the donor meets the requirements of &#167;&#8201;640.65(b)(2)(i) through |
| if             | However, you must defer the donor  if further testing for HBV or HTLV has been                                                                          |
| if             | However, you must defer the donor  if further testing for HBV or HTLV has been                                                                          |
| if             | However, you must defer the donor  if further testing for HBV or HTLV has been                                                                          |
| when           | infection due to hepatitis B surface antigen (HBsAg) when previously tested under &#167;&#8201;610.40(a), (b), and (e) subsequently                     |
| when           | comply with the requirements under &#167;&#167;&#8201;610.46 and 610.47 when a donor tests reactive by a screening test                                 |
| when           | comply with the requirements under &#167;&#167;&#8201;610.46 and 610.47 when a donor tests reactive by a screening test                                 |
| when           | labeling requirements in subchapter H of this chapter, when a medical device contains human blood or a                                                  |
| when           | source to test lots of the following products. when                                                                                                     |
| unless         | must test each lot of the following products, unless FDA informs you that less frequent testing is                                                      |
| if             | required under &#167;&#8201;606.160(d) of this chapter, to ident if y blood and blood components previously donated by                                  |
| when           | for evidence of human immunodeficiency virus (HIV) infection when  tested under &#167;&#8201;610.40(a) and (b) or                                       |
| when           | for evidence of human immunodeficiency virus (HIV) infection when  tested under &#167;&#8201;610.40(a) and (b) or                                       |
| if             | For those ident if ied blood and blood components collected: (i) Twelve                                                                                 |
| if             | For those ident if ied blood and blood components collected: (i) Twelve                                                                                 |
| if             | (3) You must not if y consignees of the results of further testing                                                                                      |
| if             | (3) You must not if y consignees of the results of further testing                                                                                      |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | previously collected in-date blood and blood components ident if ied under paragraph (a)(1) of this section, except                                     |
| when           | that are manufactured using validated viral clearance procedures, when  notified by the collecting establishment.                                       |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| when           | When further testing for HIV is positive or when the screening test is reactive and further testing                                                     |
| when           | When further testing for HIV is positive or when the screening test is reactive and further testing                                                     |
| if             | reactive and further testing is not available, or if under an IND or IDE is exempted for                                                                |
| if             | You must not if y the recipient's physician of record or a                                                                                              |
| if             | You must not if y the recipient's physician of record or a                                                                                              |
| if             | must make reasonable attempts to perform the not if ication within 12 weeks after receiving the results                                                 |
| if             | must make reasonable attempts to perform the not if ication within 12 weeks after receiving the results                                                 |
| if             | required under &#167;&#8201;606.160(d) of this chapter, to ident if y blood and blood components previously donated by                                  |
| when           | for evidence of hepatitis C virus (HCV) infection when tested under &#167;&#8201;610.40(a) and (b) of this chapter                                      |
| when           | for evidence of hepatitis C virus (HCV) infection when tested under &#167;&#8201;610.40(a) and (b) of this chapter                                      |
| if             | For those ident if ied blood and blood components collected: (i) Twelve                                                                                 |
| if             | For those ident if ied blood and blood components collected: (i) Twelve                                                                                 |
| if             | (3) You must not if y consignees of the results of further testing                                                                                      |
| if             | (3) You must not if y consignees of the results of further testing                                                                                      |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | follow an appropriate system for the following actions: if                                                                                              |
| when           | that are manufactured using validated viral clearance procedures, when  notified by the collecting establishment.                                       |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| if             | or the results of the reactive screening test if  further testing is not available, or                                                                  |
| when           | the further testing for HCV is positive or when the screening test is reactive and further testing                                                      |
| when           | the further testing for HCV is positive or when the screening test is reactive and further testing                                                      |
| if             | reactive and further testing is not available, or if under an IND or IDE, is exempted for                                                               |
| if             | You must not if y the recipient's physician of record or a                                                                                              |
| if             | You must not if y the recipient's physician of record or a                                                                                              |
| if             | must make reasonable attempts to perform the not if ication within 12 weeks after receiving the results                                                 |
| if             | must make reasonable attempts to perform the not if ication within 12 weeks after receiving the results                                                 |
| when           | (a) When the dating period begins. when                                                                                                                 |
| when           | In using the table in this paragraph,  when a product in column A is stored at                                                                          |
| unless         | exceed the dating period specified in column C, unless a different dating period is specified in the                                                    |
| if             | statement may be placed on the package label. if                                                                                                        |
| where          | stating how the Medication Guide is provided, except where the container label is too small, the required                                               |
| if             | (c) The lot number or other lot ident if ication; (d) The expiration date; (e) The preservative                                                         |
| if             | (c) The lot number or other lot ident if ication; (d) The expiration date; (e) The preservative                                                         |
| when           | or the equivalent, as well as other instructions, when indicated by the character of the product; (j)                                                   |
| if             | of the product; (j) The recommended individual dose if the enclosed container(s) is a multiple-dose container; (k)                                      |
| when           | or the equivalent, as well as other instructions, when indicated by the character of the product; (j)                                                   |
| if             | of the product; (j) The recommended individual dose if the enclosed container(s) is a multiple-dose container; (k)                                      |
| when           | or the equivalent, as well as other instructions, when indicated by the character of the product; (j)                                                   |
| where          | identity of each microorganism used in manufacture, and, where applicable, the production medium and the method of                                      |
| if             | of the product; (j) The recommended individual dose if the enclosed container(s) is a multiple-dose container; (k)                                      |
| when           | and character which can be read with ease when held in a good light and with normal                                                                     |
| if             | label, and on the label of the container if  capable of bearing a full label.                                                                           |
| provided that  | of a product may appear on the label provided that the name, address, and license number of the                                                         |
| provided that  | to which the product is to be exported provided that in all such cases the minimum label requirements                                                   |
| if             | and not explicitly required by statute, for spec if ied lots, batches, or other units of a                                                              |
| subject to     | units of the biological product that would be subject to the exception or alternative; (ii) Identify the labeling                                       |
| subject to     | units of the biological product that would be subject to the exception or alternative; (ii) Identify the labeling                                       |
| subject to     | Center Director so that the labeling of product subject to the exception or alternative includes the information necessary                              |
| if             | your annual report under &#167;&#8201;601.12(f)(3) of this chapter. if                                                                                  |


## Entities

| Entities                      | Context                                                                                                                                                 |
|:------------------------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                          | Food  and Drugs.                                                                                                                                        |
| Research                      | to the Director, Center for Biologics Evaluation and Research  (see mailing addresses in &#167;&#8201;600.2(c) of this chapter).                        |
| Research                      | by the Director, Center for Biologics Evaluation and Research , a manufacturer shall not distribute a lot                                               |
| Research                      | by the Director, Center for Biologics Evaluation and Research , a manufacturer shall not distribute a lot                                               |
| Research                      | to the Director, Center for Drug Evaluation and Research (see mailing addresses in &#167;&#8201;600.2(c) of this chapter)                               |
| Research                      | by the Director, Center for Drug Evaluation and Research , a manufacturer shall not distribute a lot                                                    |
| Potency                       | Potency .                                                                                                                                               |
| Sterility                     | Sterility .                                                                                                                                             |
| Sterility                     | Sterility testing must be performed on final container material                                                                                         |
| Plasma                        | Blood, Cryoprecipitated Antihemophilic Factor, Platelets, Red Blood Cells, Plasma , Source                                                              |
| Research                      | Director of the Center for Biologics Evaluation and Research or the Director of the Center for Drug                                                     |
| Purity                        | Purity .                                                                                                                                                |
| Research                      | by the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                          |
| Appropriate                   | Appropriate records for residual moisture under paragraph (a)(1) of                                                                                     |
| Cryoprecipitate               | the following products: Products containing formed blood elements; Cryoprecipitate ; Plasma; Source Plasma; Normal Horse Serum; bacterial,              |
| Plasma                        | following products: Products containing formed blood elements; Cryoprecipitate; Plasma ; Source                                                         |
| Normal Horse Serum            | containing formed blood elements; Cryoprecipitate; Plasma; Source Plasma; Normal Horse Serum ; bacterial, viral, and rickettsial vaccines and antigens; |
| Streptokinase                 | immune globulins derived from human blood; (ii) for Streptokinase , the test dose shall be at least                                                     |
| Test                          | (2)  Test  procedure, results, and interpretation; standards to be met.                                                                                 |
| United States Pharmacopeia XX | be performed according to the requirements specified in United States Pharmacopeia XX .                                                                 |
| Retest                        | (3)  Retest .                                                                                                                                           |
| Identity                      | Identity .                                                                                                                                              |
| Identity                      | Identity may be established either through the physical or                                                                                              |
| Research                      | by the Director, Center for Biologics Evaluation and Research  or the Director, Center for Drug Evaluation and                                          |
| Extraneous                    | Extraneous protein known to be capable of producing allergenic                                                                                          |
| Total                         | Total  solids in serums.                                                                                                                                |
| Cell                          | Cell lines used for manufacturing biological products shall be:                                                                                         |
| Test                          | Test for Except as provided otherwise in this subchapter,                                                                                               |
| Mycoplasma                    | pool shall be tested for the presence of Mycoplasma , as follows:                                                                                       |
| Test                          | Test  requirements.                                                                                                                                     |
| West Nile                     | &#167;&#8201;630.3(h)(1)(iv) through (vii) of this chapter (HTLV, syphilis, West Nile  virus, and Chagas disease).                                      |
| West Nile                     | &#167;&#8201;630.3(h)(1)(iv), (vi), and (vii) of this chapter (HTLV, West Nile  virus, and Chagas disease).                                             |
| West Nile                     | &#167;&#8201;630.3(h)(1)(iv) through (vii) of this chapter (HTLV, syphilis, West Nile virus, and Chagas disease): (A) If, based on                      |
| Prepare                       | Manufacturing Use as a Component of, or to Prepare , a Medical Device.&#8221;                                                                           |
|                               |               (3) Samples.                                                                                                                              |
| Human                         | Human blood or blood components that are required to                                                                                                    |
| Donor                         | Donor  deferral.                                                                                                                                        |
| Human                         | Human  immunodeficiency virus (HIV) “lookback” requirements.                                                                                            |
| Research                      | by the Director, Center for Biologics Evaluation and Research , in a biologics license application or supplement                                        |
| Package                       | Package  label.                                                                                                                                         |
| U.S                           | or, if potency is a factor and no U.S . standard of potency has been prescribed, the                                                                    |
| Proper                        | Proper  name; package label; legible type.                                                                                                              |
| Typography                    | Typography , layout, contrast, and other printing features shall                                                                                        |
| Legible                       | &#8220; Legible type&#8221; is type of a size and character                                                                                             |
| Name                          | Name  and address of distributor.                                                                                                                       |
| Labels                        | Labels on packages or containers of products for export                                                                                                 |
| Bar                           | Bar  code label requirements.                                                                                                                           |
| Biological                    | Biological products must comply with the bar code requirements                                                                                          |
| Explain                       | subject of the exception or alternative request; (iii) Explain why compliance with such labeling provision(s) could adversely                           |


